跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NRG-4
首页
药物
NRG-4
NRG-4
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
US 7745638 B2
申请人: ASTEX THERAPEUTICS LTD
优先权: 2007
US
6 件公开
Neuregulin-4 compounds and methods of use
US 11242370 B2
申请人: LILLY CO ELI
优先权: 2019
CN
US
4 件公开
Growth factor which acts through erb b-4 rtk
US 7094882 B2
申请人: YEDA RES & DEV
优先权: 2002
US
4 件公开
Combinations of pyrazole kinase inhibitors
US 8404718 B2
申请人: CURRY JAYNE ELIZABETH
优先权: 2010
US
2 件公开
Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
US 6544759 B1
申请人: YEDA RES & DEV
优先权: 2000
US
PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES
US 2010160324 A1
申请人: ASTEX THERAPEUTICS LTD
优先权: 2005
US
Thiazole And Isothiazole Derivatives That Modulate The Activity Of CDK, GSK And Aurora Kinases
US 2008312223 A1
申请人: ASTEX THERAPEUTICS LTD
优先权: 2005
US
MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS
US 2009318430 A1
申请人: ASTEX THERAPEUTICS LTD
优先权: 2007
US
药物
反馈